Pre-market Shock: ARS Pharmaceuticals Faces Setback
- September 20th, 2023
- 516 views
Shares of ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) plunged over 40% following the announcement that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis for adults and children weighing 30 kg or more. The company plans to submit a Formal Dispute Resolution Request (FDRR) to appeal the FDA's decision.
The FDA's request for a pharmacokinetic/pharmacodynamic study assessing repeat doses of neffy aims to support approval, despite the prior recommendation of the FDA Advisory Committee (PADAC) in May 2023 to approve neffy without the need for additional studies to demonstrate its efficacy or safety, also indicating a favorable benefit-risk profile for ARS Pharmaceuticals' intranasal epinephrine product.
$SPRY was trading at $3.51 in pre-market, reflecting a substantial decline of $3.09 (-46.85%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login